





















































Pharmaceuticals – Pipeline Overview¹ (as of July 31, 2023)

Phase 0 ²	Phase I	Phase II	Phase III
DGKalpha Inh (BAY 2862789)  ●	Elimusertib (ATR Inhibitor) (BAY 1895344)  ●	Regorafenib (combi Nivolumab) (BAY 734506)  ○	Copanlisib (PI3K Inhibitor)  ○
PSMA TAC (BAY 3546828)  ●	AhR Inhibitor (BAY 2416964)  ●	Asundexian (FXIa Inhibitor) (BAY 2433334)  ●	Darolutamide (AR Inhibitor)  ○
PSMA SMOL TAC (BAY 3563254)  ●	mEGFR Inhibitor (BAY 2927088)  ●	Zabedoseritib (IRAK4 Inh.) (BAY 1834845)  ●	Finerenone (MR Antagonist)  ○
VVD STAT3 Inh (BAY 3630914)  ●	DGKzeta Inhibitor (BAY 2965501)  ●	Runcaciguat (sGC Activator) (BAY 1101042)  ●	Vericiguat (sGC Stimulator)  ○
Anti-coagulant (BAY 3389934)  ●	CCR8 Ab (BAY 3375968)  ●	Asundexian (FXIa Inhibitor) (BAY 2433334)  ●	Asundexian (FXIa Inhibitor) (BAY 2433334)  ●
Next Generation Liver MRI (BAY 3393081)  ●	VVD KEAP1 Act (VVD-13307 aka NRF2 Inh, BAY 3605349)  ●	Finerenone (MR Antagonist) (BAY 1101042)  ●	Finerenone (MR Antagonist) (BAY 1101042)  ○
	Congestive Heart Failure rAAV Gene Therapy (AB-1002 aka NAN-101)  ●		Vericiguat (sGC Stimulator) (BAY 1101042)  ○
	sGC Activator Oral (BAY 3283142)  ●		Asundexian (FXIa Inhibitor) (BAY 2433334)  ●
	Anti-a2AP (BAY 3018250)  ●		Asundexian (FXIa Inhibitor) (BAY 2433334)  ●
	sGC Activator Inhale (BAY 1211163)  ●		Elinzanetant (Neurokinin-1,3 Rec Antagonist)  ●
	SEMA 3a (BAY 3401016)  ●		Aflibercept 8mg (VEGF Inhibitor)  ○
	Bemdaneprocel (Parkinson's Disease Cell Therapy) (BRT-DA01)  ●		Gadoquatrane (High Relaxivity Contrast Agent)  ●
	Parkinson's Disease rAAV Gene Therapy (AB-1005 aka AAV2-GDNF-PD)  ●		
	Multiple System Atrophy rAAV Gene Therapy (AB-1005 aka AAV2-GDNF-MSA)  ●		
	Pompe Disease rAAV Gene Therapy (ACTUS-101)  ●		
	Huntington's Disease rAAV Gene Therapy (AB-1001 aka BV-101)  ●		
	LGMD2I/R9 rAAV Gene Therapy (AB-1003 aka LION-101)  ●		
	GPR84 Antagonist (BAY 3178275)  ●		

-  Oncology
-  Cardiovascular+⁵
-  Neurology & Rare Diseases
-  Immunology
-  Others

-  New molecular entity
-  Life cycle management

Submissions
Aflibercept 8mg (VEGF-Inhibitor)  ○
EU, JP, US ⁴ ; Diabetic Macular Edema (DME)
EU, JP, US ⁴ , CN; Neovasc. Age-rel. Macular Degen. (nAMD)

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit ² Pre-clinical selected assets on path to IND ³ Conducted by Merck & Co ⁴ US submission made by Regeneron ⁵ Including Precision Cardiovascular, Nephrology & Acute Care

